India's Leading Hospital Chains: Q2 FY27 Comparison

India's hospital sector continues to benefit from rising healthcare demand, higher occupancy & capacity expansion. The focus now shifts to execution, margin improvement & returns on incremental capital. Manipal Hospital ( MANIPALHOS ) • Guidance: Targeting 80% network occupancy without significant capex. Sahyadri's EBITDA margin target is 23-24% over 4-5 years. • Investor view: Improving utilisation & Sahyadri integration offer operating leverage. Monitor clinical mix, patient volumes & margin delivery. Max Healthcare • Guidance: Brownfield beds expected to ramp up quickly. Max Smart's 260 new beds achieved EBITDA breakeven within three months. • Investor view: Strongest execution story among peers. Replicating quick ramp-ups across its expansion pipeline while protecting margins remains key. Fortis Healthcare • Guidance: FY27 EBITDA margin expected to remain broadly stable. FY29 margin ambition is 29%, subject to regulatory clarity on drug pricing. • Investor view: Improving operations are encouraging, but regulatory uncertainty limits margin visibility. Better clarity could support its longer-term profitability target. Medanta • Guidance: Plans 3,450 additional beds with over ₹6,000 crore capex over 4-5 years. Noida turned EBITDA-positive in Q2. • Investor view: Strong growth & operating leverage, but expansion brings execution and capital-efficiency risks. Occupancy ramp-up across new hospitals will be crucial. Investor Takeaway • Max Healthcare: Most favourable, backed by strong execution & capacity ramp-up. • Manipal: Positive, with an attractive utilisation & integration opportunity. • Medanta: Positive, but monitor capex execution & returns. • Fortis: Cautiously positive, given regulatory uncertainty. Our view: The key differentiator will be converting new capacity into sustainable occupancy, cash flows & attractive returns on capital. Management guidance is indicative & subject to execution & external factors.